HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House Co-signs Banking For Hemp Industry

Using Cannabinoids In Supplements Remains Unlawful Under FDA Regulations

Executive Summary

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

You may also be interested in...



Science Board Meeting Could Launch US Toward Lawful Hemp Use, Or Extend Market Limbo

Questions FDA is asking advisors and the public could generate answers propelling it toward determining whether hemp use in supplements should be lawful with a waiver of its prohibition against using ingredients studied or approved as a drug; or, the answers could stop the FDA in its feet.

US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate

Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.

After US FDA Objects To CBD Safety As NDIs, Supplement Industry Responds, What Else Is New?

Rejection of two firms’ proposals for using hemp-derived CBD in supplement isn’t stirring US businesses selling CBD supplements to pull products from market. For one firm that filed an unsuccessful NDI notification for full-spectrum hemp extract CBD, FDA rejection was agenda item with numerous other business, regulatory and legislative developments in its latest quarter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel